Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Impact of HER2 Heterogeneity on the Treatment of Early-stage HER2-positive Breast Cancer: a Phase II Study of T-DM1 in Combination With Pertuzumab in the Preoperative Setting

NCT02326974 is registered in ClinicalTrials.gov with Dana-Farber Cancer Institute as lead sponsor.

NCT NCT02326974
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02326974 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Impact of HER2 Heterogeneity on the Treatment of Early-stage HER2-positive Breast Cancer: a Phase II Study of T-DM1 in Combination With Pertuzumab in the Preoperative Setting
Lead sponsor
Dana-Farber Cancer Institute
Phase
Phase 2
Overall status
Active, not recruiting
Start date
January 31, 2015
Completion date
January 31, 2028
Enrollment
164 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, her-2 positive breast cancer, stage ii breast cancer, stage iii breast cancer